The company describes a narrow mid-to-lower facial wrinkle indication and a phased commercial rollout in China.
Sofwave China indication: what is confirmed?
The Sofwave China indication covers improvement of mid-to-lower facial wrinkles in adults aged 22 or older, according to a company statement released on 3 November. Sofwave said the National Medical Products Administration approved the system during the third quarter of 2026. This is not a new 3 November approval.
The date of the regulatory decision matters because an earnings announcement can repeat an earlier milestone. The company said a 200-person randomised controlled study in China supported its submission. However, the original NMPA certificate was not independently retrieved for this report.
Why the precise wording matters
A device can have different authorised uses in different countries. A clearance or approval for one concern does not automatically cover other areas or conditions. Sofwave has other stated uses in the United States.
However, those US indications should not be copied into a description of the Chinese authorisation. The company specifically described a mid-to-lower facial wrinkle indication for adults aged 22 or older. Claims about other uses in mainland China need separate confirmation.
Clinicians should check local documentation before advertising a device.
What the rollout looks like
Sofwave said it works with HTDK for marketing, distribution and sales in mainland China. The company reported an initial order for 70 systems. It shipped ten during the third quarter.
It expected to ship another 60 during the fourth quarter. These are company-reported figures. The future shipments had not occurred when the release appeared.
The company also described physician education and a phased rollout among selected accounts. That may support adoption, but it does not establish how often clinics will use the systems.
What does the clinical study establish?
The company referred to a randomised controlled study with 200 subjects in China. However, the earnings release did not provide enough study detail to judge all outcomes. It did not allow an independent review of the full protocol, statistical analysis or adverse-event reporting.
Therefore, readers should not treat the trial’s existence as proof of a broad range of benefits. The relevant endpoints, follow-up and safety findings must be checked in the original clinical report or regulator documents.
What the market should watch
The next developments are wider commercial availability, treatment use and real-world safety reporting. For clinics, the important questions include training, authorised use and patient selection. For manufacturers, the key issue is whether the Chinese rollout becomes repeatable demand.
This announcement shows progress in market entry. It does not establish that the technology outperforms competing devices. Clear regulatory wording and transparent clinical evidence remain essential.
Original source (clickable): Primary-source document
Original source date: 3 November earnings update; approval occurred Q3 2026
This article is published by Aesthetics.news for general information and educational purposes only. It does not constitute medical advice, diagnosis or treatment, and should not replace a consultation with a qualified healthcare professional. Treatments and outcomes may vary from person to person. Readers should seek advice from an appropriately qualified professional before making decisions about their health or treatment. In a medical emergency, seek immediate medical assistance.